Prostate Cancer Clinical Trial
Diffusion Basis Spectrum Imaging of the Prostate
Summary
Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.
Eligibility Criteria
Inclusion Criteria:
Over 18 years of age and willing and able to provide informed consent.
Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate biopsy as clinical standard of care ("early detection cohort")
Including those men with:
an elevated PSA and no prior biopsy
an elevated PSA and a negative prior biopsy
Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")
Exclusion Criteria:
Patients with any clinical contraindication to MRI
*Including but not limited to:
Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
Those with cochlear implants
Those with claustrophobia not relieved with medications (patients with claustrophobia who do not need medications for the scan or whose claustrophobia can be managed with medication, are eligible to participate)
Those who cannot lie flat for over 1 hour
Patients with prior prostate surgery for prostate cancer (e.g. radical prostatectomy, focal ablation)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Saint Louis Missouri, 63110, United States More Info
Principal Investigator
Sub-Investigator
Sub-Investigator
How clear is this clinincal trial information?